- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00388453
Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease (ADHERE)
24. Mai 2017 aktualisiert von: Michael Vaezi, Vanderbilt University Medical Center
ADHERE Study: Application of Dx-pH Catheter for Extra-esophageal Reflux Evaluation
The purpose of this study is to establish the clinical application of a new device that records pH changes in the hypopharynx.
The investigators also aim to compare the consistency of distal esophageal pH with hypopharyngeal pH using both the "short" and the "long" catheters in patients.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Gastroesophageal reflux disease (GERD) has been linked to many disorders and can be diagnosed through a variety of modalities utilizing 24 hour ambulatory pH monitoring which can register the duration, pattern and symptom correlation of distal esophageal acid exposure.
This can be accomplished via a catheter probe connected from outside the body and placed through a nostril, advanced past the hypopharynx and down into the distal esophagus.
Or, a small pH detector temporarily implanted in the distal esophagus during endoscopy can record reflux events.
However, despite available technologies, there has long been a deficiency in detecting extra-esophageal reflux in the upper esophagus/ hypopharynx.
This is of interest for gastroenterologists, otolaryngologists, and pulmonologists in the evaluation of extra-esophageal reflux as a potential culprit for asthma, chronic cough, laryngitis, globus, and non-cardiac chest pain.
Until now, there has not been a device sensitive enough for accurately detecting extra-esophageal reflux (EERD) and clinicians have relied upon subjective response to empiric treatment with acid reducing medications to determine whether acid reflux was at the root of the symptoms.
There are currently no well designed published studies with this device to assess its role in this group of difficult to treat patients.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
47
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt Medical Center
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Male and female volunteers aged 18 to 65 years old.
- Control group: No known history of GERD or EERD or prior PPI use.
- GERD group: Patients with known history of GERD based on prior response to either histamine inhibitors (H2 blockers) or proton pump inhibitors (PPIs) and/or endoscopic esophagitis identified at endoscopy.
- EERD group: Patients with chronic cough, asthma and laryngeal findings felt to be GERD related.
Exclusion Criteria:
- Use of H2 blockers or PPIs within one week prior to and during the study for the GERD and EERD patients. No prior PPI use is allowed for the control population.
- Use of antacids (Rolaids, Tums, Pepto-Bismol, etc.) within one day prior to or during the study.
- Esophageal motility abnormalities (achalasia, esophageal spasm, severe dysphagia)
- Expected non-compliance.
- Positive history of ongoing alcohol or tobacco use and inability to refrain from using either during study duration (24 hours).
- Recent nasal surgery or nasal obstruction.
- Significant medical conditions that, in the investigator's judgment, would compromise the subject's health and safety (mental disability, psychiatric impairment, inability to read or comprehend the consent form)
- Pregnancy
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: 1
Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
|
24 hour ph monitoring
procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
|
|
Experimental: 2
subject is known to have GERD based on symptoms and previous positive response to PPI
|
24 hour ph monitoring
procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
|
|
Experimental: 3
subject is known to have EERD based on symptoms and previous positive response to PPI
|
24 hour ph monitoring
procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Decrease in pH From Baseline to <4
Zeitfenster: 24 hours
|
The three study groups underwent dual pH measurements of the oropharyngeal as well as esophageal acid exposure employing the regular length probe for the oropharynx and the custom-designed long probe for the distal esophagus.
The reason for the custom-designed esophageal measurement was to ensure that events noted in the oropharynx originated distally and were of gastric source.
Measurements for the two locations were time synchronized to ensure accuracy.
Calculations were based on length of time spent in upright and supine positions, and a combination of the two positions.
|
24 hours
|
|
Decrease in pH From Baseline to <5
Zeitfenster: 24 hours
|
The three study groups underwent dual pH measurements of the oropharyngeal as well as esophageal acid exposure employing the regular length probe for the oropharynx and the custom-designed long probe for the distal esophagus.
The reason for the custom-designed esophageal measurement was to ensure that events noted in the oropharynx originated distally and were of gastric source.
Measurements for the two locations were time synchronized to ensure accuracy.
Calculations were based on length of time spent in upright and supine positions, and a combination of the two positions.
Reflux event was calculated for a drop in pH from baseline to either <4, or <5, or <6 and each event had to last more than 5 seconds and could not be during the meals.
|
24 hours
|
|
Decrease in pH From Baseline to <6
Zeitfenster: 24 hours
|
The three study groups underwent dual pH measurements of the oropharyngeal as well as esophageal acid exposure employing the regular length probe for the oropharynx and the custom-designed long probe for the distal esophagus.
The reason for the custom-designed esophageal measurement was to ensure that events noted in the oropharynx originated distally and were of gastric source.
Measurements for the two locations were time synchronized to ensure accuracy.
Calculations were based on length of time spent in upright and supine positions, and a combination of the two positions.
Reflux event was calculated for a drop in pH from baseline to either <4, or <5, or <6 and each event had to last more than 5 seconds and could not be during the meals.
|
24 hours
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Reflux Events
Zeitfenster: 24 hours
|
Reflux event was calculated for a drop in pH from baseline to <6 and each event had to last more than 5 seconds and could not be during the meals.
|
24 hours
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Michael F Vaezi, MD, PhD, MS, Vanderbilt University
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Oktober 2006
Primärer Abschluss (Tatsächlich)
1. September 2012
Studienabschluss (Tatsächlich)
1. Juli 2013
Studienanmeldedaten
Zuerst eingereicht
13. Oktober 2006
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
13. Oktober 2006
Zuerst gepostet (Schätzen)
16. Oktober 2006
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
27. Juni 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
24. Mai 2017
Zuletzt verifiziert
1. Mai 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 060860
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .